Abstract
The addition of ubiquitin (Ub) and ubiquitin-like (Ubl) modifiers to proteins serves to modulate function and is a key step in protein degradation, epigenetic modification and intracellular localization. Deubiquitinating enzymes and Ubl-specific proteases, the proteins responsible for the removal of Ub and Ubls, act as an additional level of control over the ubiquitin-proteasome system. Their conservation and widespread occurrence in eukaryotes, prokaryotes and viruses shows that these proteases constitute an essential class of enzymes. Here, we discuss how chemical tools, including activity-based probes and suicide inhibitors, have enabled (i) discovery of deubiquitinating enzymes, (ii) their functional profiling, crystallographic characterization and mechanistic classification and (iii) development of molecules for therapeutic purposes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kirkin, V. & Dikic, I. Role of ubiquitin- and Ubl-binding proteins in cell signaling. Curr. Opin. Cell Biol. 19, 199–205 (2007).
Kerscher, O., Felberbaum, R. & Hochstrasser, M. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu. Rev. Cell Dev. Biol. 22, 159–180 (2006).
Wilkinson, K.D., Ventii, K.H., Friedrich, K.L. & Mullally, J.E. The ubiquitin signal: assembly, recognition and termination - symposium on ubiquitin and signaling. EMBO Rep. 6, 815–820 (2005).
Pickart, C.M. & Eddins, M.J. Ubiquitin: structures, functions, mechanisms. Biochim. Biophys. Acta 1695, 55–72 (2004).
Rumpf, S. & Jentsch, S. Functional division of substrate processing cofactors of the ubiquitin-selective Cdc48 chaperone. Mol. Cell 21, 261–269 (2006).
Swaminathan, S., Amerik, A.Y. & Hochstrasser, M. The Doa4 deubiquitinating enzyme is required for ubiquitin homeostasis in yeast. Mol. Biol. Cell 10, 2583–2594 (1999).
Ryu, K.Y. et al. The mouse polyubiquitin gene UbC is essential for fetal liver development, cell-cycle progression and stress tolerance. EMBO J. 26, 2693–2706 (2007).
Nikko, E. & Andre, B. Evidence for a direct role of the Doa4 deubiquitinating enzyme in protein sorting into the MVB pathway. Traffic 8, 566–581 (2007).
Stegmeier, F. et al. Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities. Nature 446, 876–881 (2007).
Ovaa, H. et al. Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells. Proc. Natl. Acad. Sci. USA 101, 2253–2258 (2004).
Machida, Y.J. et al. UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol. Cell 23, 589–596 (2006).
Nicholson, B., Marblestone, J.G., Butt, T.R. & Mattern, M.R. Deubiquitinating enzymes as novel anticancer targets. Future Oncol. 3, 191–199 (2007).
Brooks, C.L. & Gu, W. p53 ubiquitination: Mdm2 and beyond. Mol. Cell 21, 307–315 (2006).
Stevenson, L.F. et al. The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J. 26, 976–986 (2007).
Graner, E. et al. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell 5, 253–261 (2004).
Janssen, J.W.G., Schleithoff, L., Bartram, C.R. & Schulz, A.S. An oncogenic fusion product of the phosphatidylinositol 3-kinase p85 beta subunit and HUMORF8, a putative deubiquitinating enzyme. Oncogene 16, 1767–1772 (1998).
Trompouki, E. et al. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappa B activation by TNFR family members. Nature 424, 793–796 (2003).
Brummelkamp, T.R., Nijman, S.M.B., Dirac, A.M.G. & Bernards, R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappa B. Nature 424, 797–801 (2003).
Kovalenko, A. et al. The tumour suppressor CYLD negatively regulates NF-kappa B signalling by deubiquitination. Nature 424, 801–805 (2003).
Jensen, D.E. & Rauscher, F.J. Defining biochemical functions for the BRCA1 tumor suppressor protein: analysis of the BRCA1 binding protein BAP1. Cancer Lett. 143, S13–S17 (1999).
Nijman, S.M.B. et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 123, 773–786 (2005).
Hemelaar, J. et al. Chemistry-based functional proteomics: mechanism-based activity-profiling tools for ubiquitin and ubiquitin-like specific proteases. J. Proteome Res. 3, 268–276 (2004).
Schlieker, C. et al. Structure of a herpesvirus-encoded cysteine protease reveals a unique class of deubiquitinating enzymes. Mol. Cell 25, 677–687 (2007).
Catic, A., Misaghi, S., Korbel, G.A. & Ploegh, H.L. ElaD, a deubiquitinating protease expressed by E. coli. PLoS ONE 2, e381 (2007).
Misaghi, S. et al. Chlamydia trachomatis-derived deubiquitinating enzymes in mammalian cells during infection. Mol. Microbiol. 61, 142–150 (2006).
Evans, M.J. & Cravatt, B.F. Mechanism-based profiling of enzyme families. Chem. Rev. 106, 3279–3301 (2006).
Borodovsky, A. et al. Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme. Chem. Biol. 9, 1149–1159 (2002).
Hemelaar, J., Lelyveld, V.S., Kessler, B.M. & Ploegh, H.L. A single protease, Apg4B, is specific for the autophagy-related ubiquitin-like proteins GATE-16, MAP1–LC3, GABARAP, and Apg8L. J. Biol. Chem. 278, 51841–51850 (2003).
Hemelaar, J. et al. Specific and covalent targeting of conjugating and deconjugating enzymes of ubiquitin-like proteins. Mol. Cell. Biol. 24, 84–95 (2004).
Misaghi, S. et al. Structure of the ubiquitin hydrolase UCH-L3 complexed with a suicide substrate. J. Biol. Chem. 280, 1512–1520 (2005).
Cadwell, K. & Coscoy, L. Ubiquitination on nonlysine residues by a viral E3 ubiquitin ligase. Science 309, 127–130 (2005).
Ravid, T. & Hochstrasser, M. Autoregulation of an E2 enzyme by ubiquitin-chain assembly on its catalytic residue. Nat. Cell Biol. 9, 422–427 (2007).
Catic, A., Collins, C., Church, G.M. & Ploegh, H.L. Preferred in vivo ubiquitination sites. Bioinformatics 20, 3302–3307 (2004).
Kattenhorn, L.M., Korbel, G.A., Kessler, B.M., Spooner, E. & Ploegh, H.L. A deubiquitinating enzyme encoded by HSV-1 belongs to a family of cysteine proteases that is conserved across the family Herpesviridae. Mol. Cell 19, 547–557 (2005).
Schlieker, C., Korbel, G.A., Kattenhorn, L.M. & Ploegh, H.L. A deubiquitinating activity is conserved in the large tegument protein of the Herpesviridae. J. Virol. 79, 15582–15585 (2005).
Rytkonen, A. et al. SseL, a Salmonella deubiquitinase required for macrophage killing and virulence. Proc. Natl. Acad. Sci. USA 104, 3502–3507 (2007).
Zhou, H.L. et al. Yersinia virulence factor YopJ acts as a deubiquitinase to inhibit NF-kappa B activation. J. Exp. Med. 202, 1327–1332 (2005).
Artavanis-Tsakonas, K. et al. Identification by functional proteomics of a deubiquitinating/deNeddylating enzyme in Plasmodium falciparum. Mol. Microbiol. 61, 1187–1195 (2006).
Frickel, E.M. et al. Apicomplexan UCHL3 retains dual specificity for ubiquitin and Nedd8 throughout evolution. Cell. Microbiol. 9, 1601–1610 (2007).
Sulea, T., Lindner, H.A. & Menard, R. Structural aspects of recently discovered viral deubiquitinating activities. Biol. Chem. 387, 853–862 (2006).
Angot, A., Vergunst, A., Genin, S. & Peeters, N. Exploitation of eukaryotic ubiquitin signaling pathways by effectors translocated by bacterial type III and type IV secretion systems. PLoS Pathog. 3, e3 (2007).
Rytkönen, A. & Holden, D.W. Bacterial interference of ubiquitination and deubiquitination. Cell Host Microbe 1, 13–22 (2007).
Horn, M. et al. Illuminating the evolutionary history of Chlamydiae. Science 304, 728–730 (2004).
Cazalet, C. et al. Evidence in the Legionella pneumophila genome for exploitation of host cell functions and high genome plasticity. Nat. Genet. 36, 1165–1173 (2004).
Wolf, Y.I., Aravind, L. & Koonin, E.V. Rickettsiae and Chlamydiae: evidence of horizontal gene transfer and gene exchange. Trends Genet. 15, 173–175 (1999).
Graciet, E. et al. From the cover: aminoacyl-transferases and the N-end rule pathway of prokaryotic/eukaryotic specificity in a human pathogen. Proc. Natl. Acad. Sci. USA 103, 3078–3083 (2006).
Iyer, L., Burroughs, A.M. & Aravind, L. The prokaryotic antecedents of the ubiquitin-signaling system and the early evolution of ubiquitin-like beta-grasp domains. Genome Biol. 7, R60 (2006).
Xu, J. et al. Solution structure of Urm1 and its implications for the origin of protein modifiers. Proc. Natl. Acad. Sci. USA 103, 11625–11630 (2006).
Hodgins, R.R.W., Ellison, K.S. & Ellison, M.J. Expression of a ubiquitin derivative that conjugates to protein irreversibly produces phenotypes consistent with a ubiquitin deficiency. J. Biol. Chem. 267, 8807–8812 (1992).
Pickart, C.M., Kasperek, E.M., Beal, R. & Kim, A. Substrate properties of site-specific mutant ubiquitin protein (G76a) reveal unexpected mechanistic features of ubiquitin-activating enzyme (E1). J. Biol. Chem. 269, 7115–7123 (1994).
Buchberger, A. From UBA to UBX: new words in the ubiquitin vocabulary. Trends Cell Biol. 12, 216–221 (2002).
Kiel, C. & Serrano, L. The ubiquitin domain superfold: structure-based sequence alignments and characterization of binding epitopes. J. Mol. Biol. 355, 821–844 (2006).
Catic, A. & Ploegh, H.L. Ubiquitin - conserved protein or selfish gene? Trends Biochem. Sci. 30, 600–604 (2005).
Catic, A. et al. Sequence and structure evolved separately in a ribosomal ubiquitin variant. EMBO J. 26, 3474–3483 (2007).
Amerik, A.Y. & Hochstrasser, M. Mechanism and function of deubiquitinating enzymes. Biochim. Biophys. Acta 1695, 189–207 (2004).
Pickart, C.M. & Rose, I.A. Mechanism of ubiquitin carboxyl-terminal hydrolase. Borohydride and hydroxylamine inactivate in the presence of ubiquitin. J. Biol. Chem. 261, 10210–10217 (1986).
Hershko, A. & Rose, I.A. Ubiquitin-aldehyde - a general inhibitor of ubiquitin-recycling processes. Proc. Natl. Acad. Sci. USA 84, 1829–1833 (1987).
Wilkinson, K.D., Cox, M.J., Mayer, A.N. & Frey, T. Synthesis and characterization of ubiquitin ethyl-ester, a new substrate for ubiquitin carboxyl-terminal hydrolase. Biochemistry 25, 6644–6649 (1986).
Stein, R.L., Chen, Z.J. & Melandri, F. Kinetic-studies of isopeptidase-T - modulation of peptidase activity by ubiquitin. Biochemistry 34, 12616–12623 (1995).
Dang, L.C., Melandri, F.D. & Stein, R.L. Kinetic and mechanistic studies on the hydrolysis of ubiquitin C-terminal 7-amido-4-methylcoumarin by deubiquitinating enzymes. Biochemistry 37, 1868–1879 (1998).
Johnston, S.C., Larsen, C.N., Cook, W.J., Wilkinson, K.D. & Hill, C.P. Crystal structure of a deubiquitinating enzyme (human UCH-L3) at 1.8 angstrom resolution. EMBO J. 16, 3787–3796 (1997).
Kang, S.H., Park, J.J., Chung, S.S., Bang, O.S. & Chung, C. H. Strategies for assaying deubiquitinating enzymes. Methods Enzymol. 398, 500–508 (2005)
Luchansky, S.J., Lansbury, P.T. & Stein, R.L. Substrate recognition and catalysis by UCH-L1. Biochemistry 45, 14717–14725 (2006).
Hicke, L., Schubert, H.L. & Hill, C.P. Ubiquitin-binding domains. Nat. Rev. Mol. Cell Biol. 6, 610–621 (2005).
Borodovsky, A. et al. Small-molecule inhibitors and probes for ubiquitin- and ubiquitin-like-specific proteases. ChemBioChem 6, 287–291 (2005).
Tirat, A. et al. Synthesis and characterization of fluorescent ubiquitin derivatives as highly sensitive substrates for the deubiquitinating enzymes UCH-L3 and USP-2. Anal. Biochem. 343, 244–255 (2005).
Horton, R.A., Strachan, E.A., Vogel, K.W. & Riddle, S.M. A substrate for deubiquitinating enzymes based on time-resolved fluorescence resonance energy transfer between terbium and yellow fluorescent protein. Anal. Biochem. 360, 138–143 (2007).
Cooper, E.M., Hudson, A.W., Amos, J., Wagstaff, J. & Howley, P.M. Biochemical analysis of Angelman syndrome-associated mutations in the E3 ubiquitin ligase E6-associated protein. J. Biol. Chem. 279, 41208–41217 (2004).
Dawson, T.M. Parkin and defective ubiquitination in Parkinson's disease. J. Neural Transm. Suppl. 70, 209–213 (2006).
Ohta, T. & Fukuda, M. Ubiquitin and breast cancer. Oncogene 23, 2079–2088 (2004).
Bignell, G.R. et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nat. Genet. 25, 160–165 (2000).
Liu, Y., Fallon, L., Lashuel, H.A., Liu, Z.H. & Lansbury, P.T. Jr. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 111, 209–218 (2002).
Meray, R.K. & Lansbury, P.T. Jr. Reversible monoubiquitination regulates the Parkinson disease-associated ubiquitin hydrolase UCH-L1. J. Biol. Chem. 282, 10567–10575 (2007).
Wilson, S.M. et al. Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease. Nat. Genet. 32, 420–425 (2002).
Crimmins, S. et al. Transgenic rescue of ataxia mice with neuronal-specific expression of ubiquitin-specific protease 14. J. Neurosci. 26, 11423–11431 (2006).
Scheel, H., Tomiuk, S. & Hofmann, K. Elucidation of ataxin-3 and ataxin-7 function by integrative bioinformatics. Hum. Mol. Genet. 12, 2845–2852 (2003).
Burnett, B., Li, F.S. & Pittman, R.N. The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Hum. Mol. Genet. 12, 3195–3205 (2003).
Liu, Y.C. et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem. Biol. 10, 837–846 (2003).
Mermerian, A.H., Case, A., Stein, R.L. & Cuny, G.D. Structure-activity relationship, kinetic mechanism, and selectivity for a new class of ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitors. Bioorg. Med. Chem. Lett. 17, 3729–3732 (2007).
Mullally, J.E., Moos, P.J., Edes, K. & Fitzpatrick, F.A. Cyclopentenone prostaglandins of the J series inhibit the ubiquitin isopeptidase activity of the proteasome pathway. J. Biol. Chem. 276, 30366–30373 (2001).
Li, Z.M. et al. Delta 12-prostaglandin J2 inhibits the ubiquitin hydrolase UCH-L1 and elicits ubiquitin-protein aggregation without proteasome inhibition. Biochem. Biophys. Res. Commun. 319, 1171–1180 (2004).
Verbitski, S.M., Mullally, J.E., Fitzpatrick, F.A. & Ireland, C.M. Punaglandins, chlorinated prostaglandins, function as potent Michael receptors to inhibit ubiquitin isopeptidase activity. J. Med. Chem. 47, 2062–2070 (2004).
Nalepa, G., Rolfe, M. & Harper, J.W. Drug discovery in the ubiquitin-proteasome system. Nat. Rev. Drug Discov. 5, 596–613 (2006).
Mae, M. & Langel, U. Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery. Curr. Opin. Pharmacol. 6, 509–514 (2006).
Chatterjee, C., McGinty, R.K., Pellois, J.-P. & Muir, T.W. Auxiliary-mediated site-specific peptide ubiquitylation. Angew. Chem. Int. Ed. 46, 2814–2818 (2007).
Hackenberger, C.P. A synthetic kiss of death: expressed protein ligation of a ubiquitin-peptide conjugate. ChemBioChem 8, 1221–1223 (2007).
Nazif, T. & Bogyo, M. Global analysis of proteasomal substrate specificity using positional-scanning libraries of covalent inhibitors. Proc. Natl. Acad. Sci. USA 98, 2967–2972 (2001).
Choe, Y. et al. Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities. J. Biol. Chem. 281, 12824–12832 (2006).
Huang, T.T. et al. Regulation of monoubiquitinated PCNA by DUB autocleavage. Nat. Cell Biol. 8, 339–347 (2006).
Mauri, P.L. et al. Ataxin-3 is subject to autolytic cleavage. FEBS J. 273, 4277–4286 (2006).
Gredmark, S., Schlieker, C., Quesada, V., Spooner, E. & Ploegh, H.L. A functional ubiquitin-specific protease embedded in the large tegument protein (ORF64) of murine γherpesvirus 68 is active during the course of infection. J. Virol. 81, 10300–10309 (2007).
Sugawara, K. et al. Structural basis for the specificity and catalysis of human Atg4B responsible for mammalian autophagy. J. Biol. Chem. 280, 40058–40065 (2005).
Johnson, E.S. Protein modification by SUMO. Annu. Rev. Biochem. 73, 355–382 (2004).
Gan-Erdene, T. et al. Identification and characterization of DEN1, a deneddylase of the ULP family. J. Biol. Chem. 278, 28892–28900 (2003).
Acknowledgements
We thank T. DiCesare (Whitehead Institute Bioinformatics & Research Computing Group) for help with the figures. K.R.L. is a US National Institutes of Health postdoctoral fellow (F32 AI63854). C.S. is supported by a European Molecular Biology Organization long-term fellowship (187-2005).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Love, K., Catic, A., Schlieker, C. et al. Mechanisms, biology and inhibitors of deubiquitinating enzymes. Nat Chem Biol 3, 697–705 (2007). https://doi.org/10.1038/nchembio.2007.43
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.2007.43
This article is cited by
-
Improper Proteostasis: Can It Serve as Biomarkers for Neurodegenerative Diseases?
Molecular Neurobiology (2022)
-
When the chains do not break: the role of USP10 in physiology and pathology
Cell Death & Disease (2020)
-
Substituted N-(thieno[2,3-b]pyridine-3-yl)acetamides: synthesis, reactions, and biological activity
Monatshefte für Chemie - Chemical Monthly (2019)
-
Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity
Journal of Experimental & Clinical Cancer Research (2018)
-
Metal-based proteasomal deubiquitinase inhibitors as potential anticancer agents
Cancer and Metastasis Reviews (2017)